Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rollover extension of ocrelizumab in multiple sclerosis
2021-005746-15Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Feb 2022; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2021-005746-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005746-15.